AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition June 29, 2024 AutoBot News 0 This acquisition will give AbbVie acces to Celsius Therapeutics’ lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.